IRCT20200621047857N1 IRCT 2021-08-26 Kerman University of Medical Sciences The effect of oral zinc sulfate on radiotherapy-induced acute dermatitis in breast cancer The effects of oral zinc sulfate on prevention and treatment of radiation induced acute dermatitis in patients with breast cancer 2021-05-10 anticipated 150 Complete https://irct.ir/trial/55373 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Blinding description: For the two-way blinding process, after selecting patients for radiotherapy, they are told that before radiotherapy, a drug is used orally for them , which has no side effects in previous studies and can reduce the side effects of radiotherapy. Finally, we ask the person selected for this job to bring the medicine card. The drug can be a placebo or zinc sulfate. The researcher is not aware of the nature of the drug. Each patient and the drug used for him are identified by the same number. For example, patient number 8 and drug number 8. 3 acute dermatitis to breast cancer radiation therapy. Intervention 1: Intervention group: This group will be treated daily with a dose of 220 mg of zinc sulfate (containing pharmacy) equivalent to 50 mg of elemental zinc, 3 times a day every 8 hours (total zinc intake 150 mg) throughout the treatment. Intervention 2: Intervention group: In this group, they will receive 220 mg (pharmaceutical content) twice and a placebo (Behsaz Arshian Daroo) twice, which will be every 8 hours (the amount of zinc received will be 100 mg in total). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information